How big is the next generation drug conjugates market today, and what are its future growth expectations?
The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.5 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to an increasing understanding of tumor biology, the success of early drug conjugates, increasing oncology, increasing investment and funding, and increasing patient advocacy and awareness.
The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to the growth of combination therapies, clinical research expansion, focus on rare diseases, strategic collaborations, and emerging bioinformatics tools. Major trends in the forecast period include advancements in monoclonal antibody technology, combination therapies with JAK inhibitors, artificial intelligence in drug development, development of biosimilars, and advancements in subcutaneous formulations.
Get Your Free Sample of The Global Next Generation Drug Conjugates Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp
What have been the primary factors driving the next generation drug conjugates market’s growth?
The rising prevalence of cancer is expected to propel the growth of the next-generation drug conjugates market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer incidence is primarily due to an aging population, lifestyle factors, environmental exposures, improved detection, genetic factors, and infectious agents. Next-generation drug conjugates help mitigate cancer by delivering targeted therapies directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics on Australia’s health and welfare., by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024, reflecting the impact of a growing population and rising cancer rates. Therefore, the rising prevalence of cancer is driving the growth of the next-generation drug conjugates market.
What are the key segments within the next generation drug conjugates market?
The next generation drug conjugatesmarket covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Order your report now for swift delivery
Which key players are shaping the next generation drug conjugates market?
Major companies operating in the next generation drug conjugates marker are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH
How will emerging trends drive the next generation drug conjugates market throughout the forecast period?
Major companies operating in the next-generation drug conjugates market are adopting a strategic partnerships approach to enhance research and development capabilities, accelerate product innovation, and expand their market presence. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, partnered with AbCellera Biologics Inc., a Canada-based biotechnology company, to develop first-in-class precision antibody-drug conjugates (ADCs) for oncology. The partnership will concentrate on the discovery, development, and commercialization of innovative antibody-drug conjugates (ADCs), starting with a program that targets a SMARCA degrader linked to a novel antibody. This strategy aims to broaden the therapeutic applications of Prelude’s small-molecule SMARCA2 selective degraders to a wider patient population, especially those with cancers unrelated to SMARCA4 mutations.
How do regional factors impact the next generation drug conjugates market, and which region is the largest contributor?
North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Next Generation Drug Conjugates Market Report 2025 Offer?
The next generation drug conjugates market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Next-generation drug conjugates refer to advanced formulations of drug conjugates designed to improve the efficacy and safety of targeted therapies. Next-generation drug conjugates utilize advanced targeting technologies and enhanced payloads to deliver potent therapies directly to disease cells with greater precision and reduced side effects.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19124
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
